Business context and reporting period
Pfizer Inc. filed this Form 10-K for the fiscal year ended December 31, 2009. Although the request identifies “2009 Q4,” this is an annual filing, not a quarterly report. Pfizer completed its cash-and-stock acquisition of Wyeth on October 15, 2009, in a transaction valued at approximately $68 billion. Consequently, 2009 includes Wyeth results only from the acquisition date, limiting comparability with 2008.
Following the acquisition, Pfizer reported two segments: Biopharmaceutical and Diversified. The filing text provided describes the financial statements and detailed MD&A as incorporated by reference, but does not include their complete figures.
Key financial metrics
| Metric | 2009 filing information |
|---|---|
| Biopharmaceutical revenue | $45.4 billion, up 3% from 2008 |
| Diversified revenue | $4.2 billion, up 17% from 2008 |
| Research and development expense | $7.8 billion, compared with $7.9 billion in 2008 and $8.1 billion in 2007 |
| International revenue | $28.3 billion, or 57% of total revenue |
| Net income, cash flow, margins, debt and balance-sheet liquidity | The provided filing text does not provide clear values; detailed statements are incorporated by reference |
Management said the economic downturn had not significantly affected liquidity and that operating cash flow, financial assets, capital-market access and available credit facilities supported its ability to meet foreseeable liquidity needs. No debt or credit-facility amounts are included in the provided text.
Material changes versus the prior comparable period
- Biopharmaceutical revenue rose 3%, including approximately $2.5 billion from legacy Wyeth products. Foreign exchange reduced segment revenue by approximately $1.7 billion, or 4%.
- Diversified revenue rose 17%, primarily reflecting approximately $764 million in acquired Wyeth revenue.
- Within legacy Pfizer products, growth in Lyrica, Sutent and Revatio and higher alliance revenue partly offset declines in Lipitor, Norvasc, Camptosar and Chantix/Champix.
- Biopharmaceutical revenue increased 6% in the U.S.; international revenue was flat, as acquired Wyeth revenue and legacy-product operating growth were offset by currency effects.
- Animal Health revenue declined 2%, reflecting foreign exchange, economic weakness, low milk prices and a planned reduction in U.S. distributor inventories.
Outlook, risks and unusual items
- The acquisition materially broadened Pfizer’s portfolio across medicines, vaccines, biologics, animal health, consumer healthcare and nutrition. Management identified integration and realization of expected synergies and cost savings as important execution risks.
- No specific revenue, earnings or cash-flow guidance is stated in the provided text. Management described strategic priorities including strengthening the pipeline, expanding in emerging markets, developing biotherapeutics and creating a lower, more flexible cost base.
- Patent expirations and challenges are significant risks. Lipitor’s U.S. basic patent, including pediatric exclusivity, expired in March 2010; a related patent was stated to expire in June 2011. Generic Effexor XR launches were expected under settlements from 2010 onward. The filing also describes patent disputes involving several major products.
- Other material risks include pricing and reimbursement pressure, potential U.S. health-care reform, regulatory and product-safety developments, foreign-exchange exposure, generic and biosimilar competition, and dependence on major products and wholesalers.
- Legal proceedings include patent, product-liability, consumer, commercial, environmental and tax matters. The filing text refers readers to incorporated financial-report disclosures for case details and contingencies; it does not provide a clear aggregate exposure here.
Important facts for investors to verify
- Review the incorporated 2009 Financial Report for consolidated revenue, net income, cash flow, margins, debt, liquidity, acquisition accounting and segment results.
- Assess the pace and cost of Wyeth integration, including whether anticipated synergies and cost reductions are achieved.
- Verify current outcomes and timing for Lipitor, Effexor XR and other material patent challenges and generic entries.
- Track the effects of foreign exchange, pricing and reimbursement changes, and health-care legislation on revenue and profitability.
- Review the incorporated legal-proceedings note for specific claims, recorded reserves and reasonably possible losses.